Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. (Q48007843)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 September 2015

Language	Label	Description	Also known as
English	Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.	scientific article published on 14 September 2015

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Claudio Cobelli

10

object named as

Claudio Cobelli

1 reference

Europe PubMed Central

7 February 2018

author name string

Kumiko Tanaka

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Yoshifumi Saisho

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Erica Manesso

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Masami Tanaka

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Shu Meguro

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Junichiro Irie

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Hiroaki Sugiura

7

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Toshihide Kawai

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Masahiro Jinzaki

9

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Hiroshi Itoh

11

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

KIND-LM Study Investigators

12

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

publication date

14 September 2015

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Clinical Drug Investigation

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

35

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

675-684

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

10

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Diabetes mellitus, fasting glucose, and risk of cause-specific death

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Body-mass index and mortality among adults with incident type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Effects of mitiglinide, a short-acting insulin secretagogue, on daily glycemic variability and oxidative stress markers in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Revised equations for estimated GFR from serum creatinine in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

The oral minimal model method

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

A model of GLP-1 action on insulin secretion in nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Risk of pancreatitis in patients treated with incretin-based therapies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

The islet-acinar axis of the pancreas: more than just insulin

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Incretin therapy and islet pathology: a time for caution

1 reference

https://api.crossref.org/works/10.1007%2FS40261-015-0331-5

21 January 2018

Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between body mass index and pancreas volume in Japanese people.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/26369653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40261-015-0331-5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26369653

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48007843&oldid=1448093267"